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AntibodyWhile radiolabelled antibodies have found great utility as PET and SPECT imaging agents in oncological investi-
gations, a notable shortcoming of these agents is their propensity to accumulate non-specifically within tumour
tissue. The degree of this non-specific contribution to overall tumour uptake is highly variable and can ultimately
lead to false conclusions. Therefore, in an effort to obtain a reliablemeasure of inter-individual differences in non-
specific tumour uptake of radiolabelled antibodies, we demonstrate that the use of dual-isotope imaging over-
comes this issue, enables true quantification of epitope expression levels, and allows non-invasive in vivo immu-
nohistochemistry. The approach involves co-administration of (i) an antigen-targeting antibody labelled with
zirconium-89 (89Zr), and (ii) an isotype-matched non-specific control IgG antibody labelled with indium-111
(111In). As an example, the anti-HER2 antibody trastuzumab was radiolabelled with 89Zr, and co-administered
intravenously together with its 111In-labelled non-specific counterpart to mice bearing human breast cancer xe-
nografts with differing HER2 expression levels (MDA-MB-468 [HER2-negative], MDA-MB-231 [low-HER2],
MDA-MB-231/H2N [medium-HER2], and SKBR3 [high-HER2]). Simultaneous PET/SPECT imaging using a MILabs
Vector4 small animal scanner revealed stark differences in the intratumoural distribution of [89Zr]Zr-
trastuzumab and [111In]In-IgG, highlighting regions of HER2-mediated uptake and non-specific uptake, respec-
tively. Normalisation of the tumour uptake values and tumour-to-blood ratios obtained with [89Zr]Zr-
trastuzumab against those obtained with [111In]In-IgG yielded values which were most strongly correlated
(R = 0.94; P = 0.02) with HER2 expression levels for each breast cancer type determined by Western blot and
in vitro saturation binding assays, but not non-normalised uptake values. Normalised intratumoural distribution





. This is an open access© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Nuclear imaging techniques such as positron emission tomography
(PET) and single-photon emission computed tomography (SPECT) often
utilise radiolabelled antibodies to visualise cancer-associated antigens lo-
cated within malignant tumours [1–6]. Antibodies can offer extremely
high binding affinities and specificities towards their target antigens.
Therefore, radiolabelled antibodies are an excellent choice for non-
invasive imaging and monitoring changes of those target antigens over a
time course, e.g. to monitor cancer treatment. Ideally, the accumulationInstitute
, Depart-
ill Hospi-
article underof the antibody imaging agentwithin tumourswould bemediated entirely
by the relevant target antigen. However, complications invariably arise
when non-specific phenomena contribute to their overall tumour uptake.
One example of suchnon-specific factors is the enhancedpermeability and
retention (EPR) effect, which stems from rapid and irregular angiogenesis
and causes antibodies to passively extravasate to tumour tissue via the
newly formed ‘leaky vasculature’ [7–9]. It is also recognised that the ne-
crotic areas that develop within poorly vascularised tumours can further
influence the distribution of pharmaceutical agents within tumours [10].
These non-specific contributions to overall tumour uptake can vary wildly
between tumour models, within one single tumour (intra-tumoural het-
erogeneity) or as a result of differential response to treatment (inter-
tumoural heterogeneity). This may reduce the sensitivity of these imaging
techniques and make false discoveries more likely [11].
Therefore, the ability to obtain an accurate measure of only specific
tumour uptake (i.e. any uptake directly mediated by the target antigen)
would allow a more informed and meaningful assessment of eachthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. (A) Western blot of tumour xenograft lysates showing the different levels of HER2
expression. (B) Saturation binding plot of [111In]In-trastuzumab on each of the cell lines
used in the study.
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and pre-clinical research investigations involving radiolabelled antibod-
ies in animal models of cancer. At the same time, the technique im-
proves statistical analysis of results, while halving the number of
animals needed to come to any conclusion.
With these aims inmind, we applied dual-isotope imaging, based on
co-administration of an antigen-targeting antibody (in this case,
trastuzumab) and an isotype-matched non-specific antibody (IgG1/κ).
These antibodies were radiolabelled with zirconium-89 and indium-
111, respectively, with distinctly different gamma emission spectra,
which allows their biodistribution profiles to be tracked individually.
This was accomplished using a MILabs Vector4 SPECT/CT system with
energy-resolved detectors and by performing image reconstructions
based on the unique γ-emission energies of each radioisotope.
Multi-isotope SPECT or SPECT/PET imaging techniques have certainly
previously been utilised in angiogenesis [12], brain [13], cardiac [14], in-
fection [15,16], and thrombus [17] imaging investigations, including in
the clinic. The most common radioisotope combinations used in these
studies are 111In/99mTc [18], 123I/99mTc [13], 131I/99mTc [19], 201Tl/99mTc
[20], 111In/177Lu [12], and 125I/111In/68Ga [17]. The combination of radio-
isotopes used here 111In/89Zr, is remarkably well-suited to dual-isotope
imaging as the principle γ-emissions resulting from the decay of 89Zr at
511 keV (β+/β− annihilation) and 909 keV are easily resolved from the
lower energy γ-emissions of 111In (171 and 245 keV), resulting in mini-
mal spectral overlap and crosstalk effects. Furthermore, the 89Zr and
111In radioisotopes also have well-matched physical half-lives of 3.3 and
2.8 days, respectively, which renders each of them compatible with the
well-characterised pharmacokinetics of antibody agents.
The purpose of the current study was to evaluate dual-isotope anti-
body imaging in terms of its ability to provide an accurate and
personalisedmeasure of specific tumour uptake and thus improve quan-
tification of antibody-based nuclear imaging. Furthermore, we investi-
gated the use of dual-isotope imaging using radiolabelled antibodies to
probe intratumoural epitope heterogeneity. To test this, 89Zr-labelled
anti-HER2 antibody trastuzumab and its non-specific 111In-labelled
counterpart were co-administered to mice bearing one of four human
breast cancer xenografts with varying HER2 expression levels. The over-
all uptake of each radiolabelled agent within the tumours and relevant
ratiometric values were subjected to correlational analysis with
empirically-determined HER2-expression levels. At the same time,
non-specific binding-corrected in vivo images were correlated to
intratumourally heterogeneous HER2 expression levels.
2. Methods and materials
2.1. General methods
All reagents were purchased from Sigma-Aldrich unless otherwise
stated and were used without further purification. The chelating agents p-
SCN-Bn-DFO and p-SCN-Bn-DTPA were purchased fromMacrocyclics Inc.
(Dallas, TX).Waterwasdeionisedusing aBarnsteadNANOpurepurification
system(ThermoScientific) andhada resistanceofN18.2MΩ cm−1 at 25 °C.
Protein concentration measurements were made on a ND-1000 spectro-
photometer (NanoDrop Technologies, Inc.). Instant thin-layer chromatog-
raphy (iTLC) was performed on glass microfiber chromatography paper
(Agilent Technologies) and strips were analysed with a Bioscan AR-2000
radio-TLC scanner (Eckert & Ziegler). pH was determined using pH indica-
tor paper (MerckMillipore). Radioactivitymeasurementsweremade using
a CRC-25R dose calibrator (Capintec, Inc.).
2.2. Cell culture
Four human breast cancer cell lines with differing expression levels
of the cancer biomarker HER2 were used in this study: MDA-MB-468
[HER2-negative], MDA-MB-231 [low-HER2], MDA-MB-231/H2N [me-
dium-HER2], and SKBR3 [high-HER2]. MDA-MB-231/H2N cells wereobtained by stable transfection of the HER2 receptor in MDA-MB-231
cells [21]. MDA-MB-231/H2N cells were a kind gift from Professor Robert
Kerbel at Sunnybrook Hospital, Toronto, Canada. All cell lines weremain-
tained in Dulbecco's Modified Eagle Medium (DMEM), supplemented
with 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL
penicillin, and 0.1mgmL−1 streptomycin. Cellswere grown in a 37 °C en-
vironment containing 5% CO2 and were harvested and passaged as re-
quired using Trypsin-EDTA solution. The cumulative length of culture
was b6 months following retrieval from liquid nitrogen storage.
2.3. Preparation of radiolabelled antibodies
Radiolabelling of trastuzumab and IgG was performed using previ-
ous described methods involving zirconium-89 [22] and indium-111
[23]. Radiolabelling yield (the amount of radionuclide incorporated
into the final product versus the starting amount) was routinely N95%,
as determined by iTLC-SG with 50 mM DTPA as the mobile phase. The
final radiochemical purity of the radiolabelled antibodies (radionuclide
associated with antibody versus non-associated radionuclide) after size
exclusion chromatography was N99%.
The immunoreactivity of [89Zr]Zr-trastuzumab, the main imaging
agent used for in vivo imaging, was determined on MDA-MB-231/H2N
cells by linear extrapolation to conditions representing infinite antigen
excess according to the method described by Lindmo et al. [24,25].
2.4. In vitro saturation binding studies
Aliquots of 2 × 105 cells were seeded in 24-well plates in warm cul-
ture medium (500 μL) and were allowed to adhere. The supernatant
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radiolabelled trastuzumab (0.3 MBq/μg; concentrations as indicated)
in phosphate buffered saline (PBS; pH 7.4; 500 μL). The cells were
then incubated at 4 °C for 2 h. The supernatant was removed and the
wells were washed twice with PBS (500 μL). Cells were then lysed
using a solution of 0.1 NNaOH (250 μL) for 30min at room temperature.
The resulting lysateswere transferred to counting tubes, combinedwith
two further washes of 0.1 N NaOH, and the amount of radioactivity was
measured using a 2480 WIZARD2 gamma counter (PerkinElmer).
2.5. In vivo studies
All animal procedures were performed in accordance with the UK
Animals (Scientific Procedures) Act 1986 andwith local ethical commit-
tee approval. Xenograft tumours were established in the right hind
flank of female BALB/c nu/numice (Harlan) by subcutaneous injection
of 5 × 106 cells in a 1:1 mixture of fresh media and BD Matrigel base-
ment membrane matrix (BD Biosciences) (100 μL).
2.6. Dual-isotope imaging experiments
When tumours reached a size of approximately 180mm3,micewere
administered a co-injection of [89Zr]Zr-Trastuzumab (0.9 ± 0.2 MBq,
10 μg) and [111In]In-IgG (3.9 ± 0.8 MBq, 10 μg) in sterile phosphate
buffered saline (100 μL) intravenously via the lateral tail vein. PET/Fig. 2. (A) PET/SPECT images ofmice bearingMDA-MB-468 tumours at 3 days post injection of
each radiolabelled agent in tumours and selected organs. (C) Tumour-to-blood ratios and (D)SPECT/CT images were acquired using a VECTor4CT scanner (MILabs)
at 72 h after injection. As a control, some mice were administered a
co-injection of [111In]In-Trastuzumab (4 MBq, 10 μg) and [89Zr]Zr-IgG
(1 MBq, 10 μg). For full experimental details, including acquisition and
reconstruction parameters, see Supporting Information. The ability of
the imaging system to simultaneously acquire images for 111In and
89Zr was evaluated using phantoms containing mixtures of known
amounts of either radionuclide (Fig. S1). Briefly, a series of five phan-
toms were used, phantoms 1 and 5 contained only 111In or 89Zr respec-
tively. Phantoms2–4 contained amixture of 89Zr and 111In. Imageswere
obtained of these phantoms with the same imaging parameters and re-
construction parameters as the in vivo studies.2.7. Ex vivo biodistribution experiments
Mice were euthanized by cervical dislocation and selected tissues
and blood were removed, immediately rinsed with water, blot dried,
and transferred into a pre-weighed counting tube. The amount of
111In and 89Zr in each sample was measured simultaneously using a
HiDex gamma counter (Lablogic). After correction for downscatter,
counts per minute were converted into radioactivity units (MBq)
using calibration curves generated from known standards. These values
were decay-corrected to the time of injection, and the percentage of the
injected dose per gram (%ID/g) of each sample was calculated.[89Zr]Zr-trastuzumab and [111In]In-IgG. (B) Biodistribution data showing uptake (%ID/g) of
tumour-to-muscle ratios for each radiolabelled agent. (ns: no statistical significance).
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Tumour xenograft tissues were used to prepare total cell lysates. Ly-
sates were separated by SDS-PAGE, and transferred to PVDFmembrane.
Membranes were blocked, and stained for HER-2 using a rabbit mono-
clonal antibody (Cell Signalling Technology 29D8-2165; 1:1000 dilu-
tion), and visualised using a horseradish peroxidase secondary
antibody (Thermo Scientific 65-6120; 1:5000). For full experimental
details, see Supporting Information.2.9. Statistical analyses
All statistical analyses and nonlinear regression were performed
using GraphPad Prism version 7 (GraphPad Software, San Diego, CA,
USA). Datawere tested for normality using a Shapiro-Wilk test. Analysis
of variance (ANOVA) with Holm-Sidak's post-test was used to calculate
the significance of differences between groups. All data were obtained
at least in triplicate and results reported asmean± standard deviation,
unless stated otherwise.Fig. 3. (A) PET/SPECT images of mice bearing MDA-MB-231 tumours at 3 days post injection o
231 tumours at 3 days post injection of [89Zr]Zr-trastuzumab, [111In]In-IgG, and a blocking dos
each radiolabelled agent in tumours and selected organs. (D) Tumour-to-blood ratios and (
*P b 0.05).3. Results
3.1. In vitro analyses
Relative HER2 expression levels in xenograft tumours established
fromeach of the four breast cancer cell lineswas visualised andquantified
usingWestern blot (Fig. 1A). The relative band intensities after normalisa-
tion to the β-actin loading control were 0, 10.0, 66.3, and 100 for MDA-
MB-468, MDA-MB-231, MDA-MB-231/H2N, and SKBR3, respectively.
The relative number of trastuzumab binding sites on each cell line
was determined by saturation binding assays using [111In]In-
trastuzumab in in vitro experiments. This revealed Bmax values of
1973 ± 135, 18,662 ± 1335, 47,473 ± 1926, and 368,644 ±
6385 cpm for MDA-MB-468, MDA-MB-231, MDA-MB-231/H2N, and
SKBR3, respectively (Fig. 1B). KD was quantified as 2.8 ± 0.23 nM.
An immunoreactive fraction of 0.96 ± 0.03 was determined for
[89Zr]Zr-trastuzumab, the main imaging agent used for in vivo imaging.
This result indicates that only a negligible degree of disruption to anti-
gen binding properties occurred as a result of the DFO-modification
and radiolabelling procedures (Fig. S2).f [89Zr]Zr-trastuzumab and [111In]In-IgG. (B) PET/SPECT images of mice bearing MDA-MB-
e (0.5 mg) of unlabelled trastuzumab. (C) Biodistribution data showing uptake (%ID/g) of
E) tumour-to-muscle ratios for each radiolabelled agent. (ns: no statistical significance;
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The ability of theMILabs VECTor4 imaging system to simultaneously
acquire images for 111In and 89Zr was evaluated using phantoms con-
taining mixtures of known amounts of either radionuclide. Samples
containing 89Zr only did not show any signal in the constructed 111In
image, or vice versa. Quantification of 111In or 89Zr was not influenced
by the presence of the other isotope (Fig. S1), corroborating earlier re-
ports on dual-isotope imaging with this system.
3.2.1. MDA-MB-468 (HER2-negative)
Representative dual-isotope images of mice bearing MDA-MB-468
xenograft tumours (Fig. 2A) and biodistribution data (Fig. 2B) revealed
that the co-administered antibodies have a highly comparable overall
biodistribution. Analysis of the biodistribution data indicated that the
uptake of [89Zr]Zr-trastuzumab and [111In]In-IgG in the HER2-negative
tumours was statistically indistinguishable (12.2 ± 3.8 and 12.7 ±
4.7%ID/g, respectively; P N 0.05). The only significant difference was in
bone which had higher 89Zr uptake compared to 111In (8.5 ± 1.4 and
3.1 ± 0.7%ID/g, respectively; P = 0.004). These values are consistent
with those from previous studies in mice involving 89Zr-DFO- andFig. 4. (A) PET/SPECT images of mice bearing MDA-MB-231/H2N tumours at 3 days post injecti
MB-231/H2N tumours at 3 days post injection of [89Zr]Zr-trastuzumab, [111In]In-IgG, and a bloc
ID/g) of each radiolabelled agent in tumours and selected organs. (D) Tumour-to-blood ratios111In-DTPA-modified antibodies [26–28] and this disparity is attributed
to differences in chelate stability and the particularly osteophilic nature
of 89Zr [29]. Despite this, it remains that the uptake of both radiolabelled
agents in the tumours and all of the other selected organs was not sta-
tistically different (Fig. 2B, Table S1; P N 0.05), indicating that the degree
of dissociated 89Zr did not significantly alter the overall biodistribution
compared to the non-specific [111In]In-IgG. In addition, the respective
tumour-to-blood (T/B; Fig. 2C) and tumour-to-muscle (T/M; Fig. 2D) ra-
tios for [89Zr]Zr-trastuzumab (0.8±0.1 and 7.1±2.4, respectively) and
[111In]In-IgG (0.7 ± 0.2 and 6.8 ± 2.5, respectively) were also similar
(P N 0.05).
Accordingly, the [89Zr]Zr-trastuzumab: [111In]In-IgG uptake ratio in
these HER2-negative tumourswas 1.0±0.1 and thiswas in close agree-
ment with volume-of-interest analysis of the reconstructed images
which yielded a ratio of 1.3±0.3 (P N 0.05). This corroboration between
imaging analysis and ex vivo biodistribution data was found for all the
tumour models used in this study (Fig. S3).
3.2.2. MDA-MB-231 (low-HER2) and MDA-MB-231/H2N (medium-HER2)
Surprisingly, overall uptake of [89Zr]Zr-trastuzumab in the MDA-
MB-231 (Fig. 3A–B) and MDA-MB-231/H2N (Fig. 4A–B) tumours wason of [89Zr]Zr-trastuzumab and [111In]In-IgG. (B) PET/SPECT images of mice bearingMDA-
king dose (0.5mg) of unlabelled trastuzumab. (C) Biodistribution data showing uptake (%
and (E) tumour-to-muscle ratios for each radiolabelled agent. (*P b 0.05; ****P b 0.0001).
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P N 0.05), despite the cell lines having different HER2 expression levels
(in vitro Bmax values were 18,662 ± 1335 and 47,473 ± 1926 cpm, re-
spectively). Similarly, T/B ratios were not different for [89Zr]Zr-
trastuzumab (1.1 ± 0.1 and 1.0 ± 0.1, respectively; P N 0.05; Figs. 3D,
4D). The T/M ratio was lower, however, for the MDA-MB-231 tumour
model compared to the MDA-MB-231/H2N model (8.41 ± 4.05 and
9.1 ± 1.6, respectively; P b 0.05; Figs. 3E, 4E). The reason for the unex-
pected lack of difference in tumour uptake and T/B ratios became clear
when the non-specific uptake of the control IgG was taken into consid-
eration. MDA-MB-231 tumours tended to show higher non-specific up-
take (13.5 ± 6.2%ID/g) compared to MDA-MB-231/H2N (6.6 ± 0.8%ID/
g; P b 0.10) (Figs. 3C, 4C). Accordingly, the [89Zr]Zr-trastuzumab: [111In]
In-IgG uptake ratios were 1.5 ± 0.5 and 2.3 ± 0.2, respectively (P =
0.31). In mice co-administered a blocking dose (0.5 mg) of unlabelled
trastuzumab, a reduction of HER2-mediated [89Zr]Zr-trastuzumab up-
take was observed, resulting in intratumoural 89Zr:111In ratios of
0.9 ± 0.1 and 1.4 ± 0.1 for MDA-MB-231 and MDA-MB-231/H2N
tumour-bearing mice, respectively. Blocking results in a ratio between
[89Zr]Zr-trastuzumab vs. [111In]In-IgG uptake in the tumour that was
not statistically significant from the theoretical value of 1 for MDA-Fig. 5. (A) PET/SPECT images of mice bearing SKBR3 tumours at 3 days post injection of [89Zr]Z
3 days post injection of [89Zr]Zr-trastuzumab, [111In]In-IgG, and a blocking dose (0.5mg) of unla
agent in tumours and selected organs. (D) Tumour-to-blood ratios and (E) tumour-to-muscleMB-231 xenografts (P= 0.42), but not for MDA-MB-231/H2N tumours
(P = 0.008).
It is worth noting that in these two tumour models, the alternative
radioisotope combination (i.e. [111In]In-trastuzumab/89Zr-IgG) was
also evaluated. In this case, uptake ratios in the tumours and all of the
selected organs were not statistically different to those obtained with
[89Zr]Zr-trastuzumab: [111In]In-IgG (P N 0.05; Fig. S4), indicating that
the selection of radioisotope combination is inconsequential. In addi-
tion, to determine any influence of additional IgG dose on the
biodistribution of the radiolabelled antibody, uptake of [89Zr]Zr-
trastuzumab with and without co-injection of 111In-labelled or non-
radiolabelled non-specific IgG control was quantified. The uptake of
[89Zr]Zr-trastuzumab was not significantly altered (P N 0.05) in MDA-
MB-231/H2N xenografts, nor in any of the normal tissues, after injection
of isotype control antibody suggesting the normalisation technique
employed here can be employed without affecting the original
measurement.
3.2.3. SKBR3 (high-HER2)
As expected, the uptake of [89Zr]Zr-trastuzumab in SKBR3 tumours
was higher compared to each of the other tumour models (34.1 ±r-trastuzumab and [111In]In-IgG. (B) PET/SPECT images of mice bearing SKBR3 tumours at
belled trastuzumab. (C) Biodistribution data showing uptake (%ID/g) of each radiolabelled
ratios for each radiolabelled agent. (***P b 0.001; ****P b 0.0001).
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and T/M (Fig. 5D) ratios were also obtained (3.0 ± 0.9 [P b 0.002] and
31.0 ± 7.1 [P b 0.002], respectively). Furthermore, the ratio of
intratumoural 89Zr:111In (3.9 ± 0.9) was significantly higher than
each of the other tumour types (P b 0.007; Fig. 6A).
In contrast with the other tumour models used in this study, the re-
spective biodistribution profiles of [89Zr]Zr-trastuzumab and [111In]In-
IgG in SKBR3 tumour-bearing mice were markedly different as signifi-
cant differences in uptake (%ID/g) were observed for most organs
(Fig. 5B). In this case, the considerable extent of HER2-mediated seques-
tration of [89Zr]Zr-trastuzumab to the tumour was likely responsible for
these differences. This sequestration effect alters the input function (i.e.
the concentration of radiolabelled antibody in blood plasma as a func-
tion of time) of [89Zr]Zr-trastuzumab compared to [111In]In-IgG and
this therefore presents an important variable factor which requires con-
sideration. Accordingly, the amount of [89Zr]Zr-trastuzumab in blood (%
ID/g) at 72 h post injectionwas selected as themost relevant normalisa-
tion parameter to reflect this disparity, and thus the T/B ratios for [89Zr]
Zr-trastuzumab and [111In]In-IgG for all tumour groups were compared
(Fig. 6B). As a result of this analysis, a comparison of [89Zr]Zr-
trastuzumab (T/B): [111In]In-IgG (T/B) ratios against the HER2 expres-
sion levels (Bmax) for each tumour type, which also revealed a strong
correlation with empirically determined HER2 expression levels than
[89Zr]Zr-trastuzumab: [111In]In-IgG tumour uptake ratios alone (R =
0.995, P = 0.0025 vs. R = 0.94, P = 0.029, respectively; Fig. 6A–D).
The conventional un-normalised [89Zr]Zr-trastuzumab uptake (%ID/g)
values were poorly correlated with HER2 expression levels (R = 0.92,
P=0.04, Fig. S6). Voxel-per-voxel subtraction of the non-specific signalFig. 6. (A) The [89Zr]Zr-trastuzumab/[111In]In-IgG uptake ratios and (B) the [89Zr]Zr-trastu
(C) Correlation between overall uptake of [89Zr]Zr-trastuzumab/[111In]In-IgG and expression l
trastuzumab T/B: [111In]In-IgG T/B ratios and expression levels of HER2 determined by saturatalso correlates well with the HER2-expresison levels Bmax values for the
tumour models used in this study (R = 0.97, P = 0.030; Fig. S7).
3.2.4. Visualising HER2-mediated uptake of [89Zr]Zr-trastuzumab
Dual isotope imaging with SPECT, or indeed performing of PET and
SPECT simultaneously has been reported before in the literature
[12–17]. However, combining a radiolabelled antibody with its own
negative control, and normalising for non-specific uptake to look at
intratumoural heterogeneity of epitope-meditated uptake has, to the
best of our knowledge, not yet been described (Fig. 7A–E). An example
of heterogeneous uptake of [89Zr]Zr-trastuzumab (i.e. HER2-mediated
and passive accumulation) in a representative low HER-2 expressing
MDA-MB-231 tumour can be observed in the magnified image shown
in Fig. 7A (red). In an identical view of the same area, non-specific up-
take of control IgG (Fig. 7B; green) can been observed pooling in a central
compartment (a necrotic region, confirmedbyH&E staining, Fig. 7E)within
the tumour. Theoverlaid images (Fig. 7C) and the imagewhich results from
subtraction of the non-specific signal from the [89Zr]Zr-trastuzumab image
(Fig. 7D) each reveal the total absence of HER2-mediated uptake of [89Zr]
Zr-trastuzumab within this central compartment.
4. Discussion
Here, we demonstrated that molecular imaging using dual isotope
imaging with antibodies is a potent tool that allows quantification of
total tumour epitope-specific uptake of the antibody and correlates
well with epitope expression levels. More strikingly, we showed that
detailed intratumoural heterogeneity of epitope expression correlateszumab T/B: [111In]In-IgG T/B ratios for each of the tumour models used in the study.
evels of HER2 determined by saturation binding assay. (D) Correlation between [89Zr]Zr-
ion binding assay. Error bars for (A) and (B) represent standard error of the mean.
Fig. 7. (A) Magnified sections of a representative tumour (MDA-MB-231) showing differences in the intratumoural distribution of [89Zr]Zr-trastuzumab (A) and [111In]In-IgG (B). Images
overlaid in (C). (D) Image resulting from subtraction of the [111In]In-IgG signal from the overlaid image showing theHER2-specific uptake of [89Zr]Zr-trastuzumab. (E–F) H&E staining and
immunohistochemistry staining HER2 in adjacent sections (blue: DAPI; green: HER2).
21J.C. Knight et al. / Nuclear Medicine and Biology 70 (2019) 14–22well with background-corrected antibody images – at least in the tu-
mour models we tested here.
For the current study, we used a MILabs VECTOR4 imaging camera,
which allows simultaneous SPECT acquisition of a range of radionu-
clides, from ‘classical’ SPECT isotopes such as 99mTc and 111In, to posi-
tron emitter such as 18F and 89Zr, using a set of pinholes [30]. Multi-
isotope imaging has been described previously [31]. Therefore, no co-
registration between SPECT and PET images was necessary. As such,
the basis of the techniquewe have used here is not new. In fact, dual iso-
tope imaging using SPECT with radiolabelled antibodies has been used
since the 1980's [32], and dual isotope SPECT imaging has been used
to e.g. visualise the fate of different parts of therapeutic nanoparticles
[33]. Non-specific uptake of antibodies, radiolabelled or otherwise, has
been known for longer than that. It should be said that molecular imag-
ing using smaller compounds, such as radiolabelled small molecules,
peptides, or antibody fragments, engineered antibody-derived proteins
such as diabodies, minibodies, affibodies and nanobodies, overcome the
issues associated with non-specific uptake of larger molecules. Nonethe-
less, because of their superior affinity and selectivity, antibodies continue
to be used as the basis for imaging agents, and radiolabelled antibodies
are being used to study the in vivo pharmacokinetics and pharmacody-
namics of immunotherapies and antibody-drug conjugates [34].
What dual isotope imaging allowed us to do, is to compensate, on a
voxel-per-voxel basis, for the non-specific component of antibody uptake
in the tumour. This enabled us to build a detailedmap of epitope-specific
uptake heterogeneity within the tumour, which correlatedwell with that
same epitope heterogeneity as assessed by immunohistochemistry.
A key limitation of themethodology used here is the inherent differ-
ence in partial volume effects between 111In and 89Zr on the voxel scale.
Here, we addressed this in first approximation by reconstruction of the
111In signal to a lower resolution than possible using the MILabs Vector
imaging system, artificially lowering the resolution of the 111In signal toa similar level of that of the 89Zr signal. Additional work is needed to ad-
dress this challenge and allow true quantitative subtraction imaging.
We postulate that the technique used here will be especially useful for
antibody-mediated imaging and quantifying lowly abundant targets such
as HER3, or intracellular targets such as γH2AX, where the epitope-
specific part of total tumour uptake is relatively low compared to non-
specific uptake (as exemplified here in the case of the MDA-MB-231/
H2N). Dual isotope imagingwill therefore also be useful for the evaluation
of experimental tumour therapies [35] to guide e.g. radiotherapy dose
painting [36] in preclinical models, or to study in detail the delivery of
antibody-drug conjugates [37]. Another advantage is the halving of the
number of animals for therapy evaluation studies. For now, we have only
evaluated dual isotope imaging in preclinical models. Modern SPECT cam-
eras for patient use are able to quantify images, but currently this approach
may be limited to non-positron emitting radioisotopes, and the financial
cost of administering two radiolabelled antibodies may prove prohibitive
to translate the technique to patients for routine imaging. The additional
radiation exposure associated with concurrent administration of two im-
aging agents is also a disadvantage. In addition, one of themain arguments
for non-specific uptake of macromolecular compounds in tumour tissue,
the enhanced perfusion and retention effect (EPR), may not be as relevant
in human patients than it is in rodents [38,39].
Our results certainly lead to questions regarding the non-specific up-
take of radiolabelled antibodies in tumour models. Why should non-
specific uptake be so different between what are, to all intents and pur-
poses, nearly identical models, the MDA-MB-231 and MDA-MB-231/
H2N xenografts, that are genetically identical apart from knock-in of
the HER2 receptor in the latter. Indeed, uptake of the non-specific anti-
body was 6.6%ID/g in the one, versus 13.5%ID/g in the other. Reasons
may include (1) differences in vascular density, vascular architecture
and fenestration; (2) differences in lymphatic drainage; and (3) differ-
ences in the EPR effect that may be further enhanced by changes in
22 J.C. Knight et al. / Nuclear Medicine and Biology 70 (2019) 14–22other phenotypic factors such as, bradykinin, nitric oxide, prostaglan-
dins, vascular endothelial growth factor, or tumour necrosis factor and
others. It is of note that the dual-isotope-based normalisation technique
described here of course takes into account all the inter-individual dif-
ferences in tumour vascularisation.
5. Conclusions
The dual-isotope method described herein provides a quantitative
and highly personalised value of epitope-specific uptake for antibody-
based radiopharmaceuticals. Normalisation of [89Zr]Zr-trastuzumab up-
take and tumour-to-blood contrast ratios to corresponding values ob-
tained with [111In]In-IgG resulted in metrics strongly correlated with
empirically determined HER2 expression levels. Furthermore, subtrac-
tion of the non-specific [111In]In-IgG signal from the [89Zr]Zr-
trastuzumab image reveals intratumoural regions of non-specific up-
takewhich otherwisewould remain obscured. This approach also offers
utility in preclinical research and development studies based on exam-
ining drug penetration, target engagement, tumour heterogeneity, radi-
ation dose painting, and beyond.
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